Common Contracts
2 similar Il-1 Antibody Termination Agreement contracts by Regeneron Pharmaceuticals Inc
ContractIl-1 Antibody Termination Agreement • May 5th, 2020 • New York
Portions of this Exhibit Have Been Omitted and Separately Filed with the Securities and Exchange Commission with a Request for Confidential Treatment
IL-1 ANTIBODY TERMINATION AGREEMENT By and Between NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CORPORATION AND REGENERON PHARMACEUTICALS, INC. Dated as of June 8, 2009Il-1 Antibody Termination Agreement • August 4th, 2009 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS IL-1 ANTIBODY TERMINATION AGREEMENT (“Agreement”), made as of June 8, 2009 (the “Effective Date”), is by and between NOVARTIS PHARMA AG, a corporation organized under the laws of Switzerland and having a principal place of business at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”), NOVARTIS PHARMACEUTICALS CORPORATION of One Health Plaza, East Hanover, New Jersey (“NPC”) and REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) (with each of Novartis and Regeneron referred to herein individually as a “Party” and collectively as the “Parties”, and with NPC being a “Party” to this Agreement for purposes of Section 2 only).
